Cargando…
A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic
BACKGROUND: Access to naloxone is essential as the overdose crisis persists. We described barriers to accessing naloxone among individuals who requested and received the medication from a free mailed program and explored the relationship between how individuals with and without personal proximity to...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373681/ https://www.ncbi.nlm.nih.gov/pubmed/33765515 http://dx.doi.org/10.1016/j.drugpo.2021.103199 |
_version_ | 1783739974252756992 |
---|---|
author | French, Rachel Favaro, Jamie Aronowitz, Shoshana V. |
author_facet | French, Rachel Favaro, Jamie Aronowitz, Shoshana V. |
author_sort | French, Rachel |
collection | PubMed |
description | BACKGROUND: Access to naloxone is essential as the overdose crisis persists. We described barriers to accessing naloxone among individuals who requested and received the medication from a free mailed program and explored the relationship between how individuals with and without personal proximity to overdose learned about the program. METHODS: Secondary analysis of data from a web-based form collected 1st March 2020 to 31st January 2021. Access barriers, personal proximity to overdose (broadly defined as personally overdosing or witnessing/worrying about others overdosing), and method of learning about the program were categorized and described. RESULTS: Among 422 respondents, the most frequently reported barriers to accessing naloxone were: COVID quarantine (25.1%), lack of knowledge about access (13.2%), and cost (11.2%). Compared to those without personal proximity to overdose (38.2%), individuals with personal proximity (61.8%) heard about the program more often through an active online search (21.4% vs. 8.8%; p-value = 0.001) and less often through word of mouth (19.8% vs. 40.9%; p-value = <0.001). CONCLUSIONS: Longstanding barriers to naloxone access are compounded by the COVID-19 pandemic, making mailing programs especially salient. Differences in ways that individuals with and without personal proximity to substance use and overdose learned about this program can inform how such programs can effectively reach their target audience. |
format | Online Article Text |
id | pubmed-8373681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83736812022-08-01 A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic French, Rachel Favaro, Jamie Aronowitz, Shoshana V. Int J Drug Policy Short Report BACKGROUND: Access to naloxone is essential as the overdose crisis persists. We described barriers to accessing naloxone among individuals who requested and received the medication from a free mailed program and explored the relationship between how individuals with and without personal proximity to overdose learned about the program. METHODS: Secondary analysis of data from a web-based form collected 1st March 2020 to 31st January 2021. Access barriers, personal proximity to overdose (broadly defined as personally overdosing or witnessing/worrying about others overdosing), and method of learning about the program were categorized and described. RESULTS: Among 422 respondents, the most frequently reported barriers to accessing naloxone were: COVID quarantine (25.1%), lack of knowledge about access (13.2%), and cost (11.2%). Compared to those without personal proximity to overdose (38.2%), individuals with personal proximity (61.8%) heard about the program more often through an active online search (21.4% vs. 8.8%; p-value = 0.001) and less often through word of mouth (19.8% vs. 40.9%; p-value = <0.001). CONCLUSIONS: Longstanding barriers to naloxone access are compounded by the COVID-19 pandemic, making mailing programs especially salient. Differences in ways that individuals with and without personal proximity to substance use and overdose learned about this program can inform how such programs can effectively reach their target audience. Elsevier B.V. 2021-08 2021-03-04 /pmc/articles/PMC8373681/ /pubmed/33765515 http://dx.doi.org/10.1016/j.drugpo.2021.103199 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Report French, Rachel Favaro, Jamie Aronowitz, Shoshana V. A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic |
title | A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic |
title_full | A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic |
title_fullStr | A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic |
title_full_unstemmed | A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic |
title_short | A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic |
title_sort | free mailed naloxone program in philadelphia amidst the covid-19 pandemic |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373681/ https://www.ncbi.nlm.nih.gov/pubmed/33765515 http://dx.doi.org/10.1016/j.drugpo.2021.103199 |
work_keys_str_mv | AT frenchrachel afreemailednaloxoneprograminphiladelphiaamidstthecovid19pandemic AT favarojamie afreemailednaloxoneprograminphiladelphiaamidstthecovid19pandemic AT aronowitzshoshanav afreemailednaloxoneprograminphiladelphiaamidstthecovid19pandemic AT frenchrachel freemailednaloxoneprograminphiladelphiaamidstthecovid19pandemic AT favarojamie freemailednaloxoneprograminphiladelphiaamidstthecovid19pandemic AT aronowitzshoshanav freemailednaloxoneprograminphiladelphiaamidstthecovid19pandemic |